To transform the lives of cancer patients by unleashing the power of highly potent tumor-selective immuno-oncology therapies. Xilio’s proprietary technology allows us to create novel immunotherapies that preferentially bind their targets in tumors while minimizing activity in healthy non-tumor tissues. This approach is intended to bring the benefits of immuno-oncology therapy to patients by minimizing toxicity while enhancing anti-tumor efficacy.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.